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  16 
Abstract 17 
Dengue vaccine development has made significant strides, but a better understanding of how 18 
vaccine-induced immune responses correlate with vaccine efficacy can greatly accelerate development, 19 
testing, and deployment as well as ameliorate potential risks and safety concerns. Advances in basic 20 
immunology knowledge and techniques have already improved our understanding of cell-mediated 21 
immunity of natural dengue virus infection and vaccination. We conclude that the evidence base is 22 
adequate to argue for inclusion of assessments of cell-mediated immunity as part of clinical trials of 23 
dengue vaccines, although further research to identify useful correlates of protective immunity is 24 
needed. 25 
  26 
Introduction 27 
The immunological basis of the efficacy of many of the most well-established vaccines is poorly 28 
understood, and, where studies to better understand vaccine efficacy have been done, they have almost 29 
always relied on tests of pathogen-specific antibodies rather than on measures of cell-mediated 30 
immunity (CMI) [1]. Several reasons likely explain this bias; serum is more easily obtained than viable 31 
lymphocytes, antibodies can be studied in isolation, and assays of antibody concentration and function 32 
are technically more straightforward and reproducible than cellular assays. Fortunately, in many cases 33 
detection of antibodies at or above a defined concentration using specific assays has proven to serve as 34 
a useful correlate of protective immunity. However, there has been ample evidence in the case of 35 
established vaccines that the information provided by assays of antibody responses is often incomplete, 36 
and that protective immunity (sometimes only partially protective) was present in some individuals 37 
without protective antibody levels. 38 
A consultation was organized by the WHO in 2007 to “review the state of the art of dengue CMI 39 
and to discuss the potential role of CMI in advancing dengue vaccine candidates towards licensure” [2]. 40 
The participants concluded that “precise function of CMI in protection or disease pathology remains ill-41 
defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of 42 
protection.” Recent data from dengue vaccine trials has renewed interest in addressing this issue, 43 
however. In the pivotal phase III trials of the Sanofi Pasteur chimeric dengue virus (DENV) – yellow fever 44 
virus (YFV) vaccine, plaque reduction neutralization titers (PRNT) only weakly correlated with protection, 45 
and breakthrough infections occurred in some individuals with high PRNT values [3, 4]. While efforts 46 
continue to refine assays of DENV-specific antibodies in order to discriminate effective/protective from 47 
ineffective/non-protective antibodies (assuming that this is possible), these findings re-emphasize the 48 
need to consider the role of DENV-specific T lymphocyte responses in vaccine efficacy. This review seeks 49 
to summarize the current state of knowledge regarding DENV-specific CMI and propose potential 50 
contributions of CMI measurements to dengue vaccine development and testing. 51 
An appraisal of the literature on DENV-specific T cell responses merits a brief review of current 52 
paradigms in T cell biology and relevant technologies. One area highlighted by recent work is the 53 
complexity of effector T cell subsets. Extending the paradigm of Th1 versus Th2 responses among CD4 T 54 
cells, at least 7 different phenotypes have now been described [5, 6]. Table 1 summarizes key proteins 55 
expressed by each subset. Cytokines and other signals produced by antigen-presenting cells during the 56 
initial T cell activation (not listed in the table) determine which pathway is taken by an individual T cell 57 
through the induction of the transcription factors listed, and this in turn controls the profile of 58 
chemokine receptors and cytokines produced. The characteristic cytokines produced by each subset are 59 
the major determinant of its role in immunity and also tend to reinforce cell polarization. The profile of 60 
chemokine receptors expressed by each cell subset determines that subset’s predominant anatomical 61 
distribution, such as peripheral versus mucosal versus secondary lymphatic sites, which also contributes 62 
to its function in the response to different pathogens. Cytolytic activity, not traditionally considered an 63 
important effector function of CD4 T cells, has been increasingly recognized, mainly among cells 64 
expressing Th1 cytokines [7]. In contrast, while cytolysis has long been seen as the main function of CD8 65 
T cells, there has been a growing recognition of more diverse subsets within this population. CD8 T cell 66 
subsets with cytokine profiles similar to several of the CD4 subsets listed in Table 1 have been described, 67 
although there is comparably less known about them. Based on studies in mice, T cell polarization has 68 
often appeared to be a fixed characteristic of the cell determined during its initial activation. However, 69 
studies in humans suggest more plasticity in T cell phenotype [8]. 70 
Another area of active research in T cell biology is the developmental relationships between 71 
naïve, effector, and memory T cells [9-11]. This topic entails significant debate, as, unlike the case with B 72 
lymphocytes, there are no universally accepted standards for defining a memory T cell; several different 73 
schemas have been proposed to define the phenotypes of effector versus memory T cells, but it is clear 74 
that these are imperfect. From a functional standpoint, it is recognized that, among antigen-experienced 75 
T cells, there is a subset of short-lived effector cells that are destined to undergo apoptosis whereas 76 
other cells demonstrate the capacity for long-term persistence and even self-renewal. Within the long-77 
lived memory cell population, heterogeneity in function and protein expression led to a distinction of 78 
central memory T cells (TCM) and effector memory T cells (TEM). Recent data have revealed further 79 
complexity, and led to the classification of several additional subsets such as tissue-resident memory T 80 
cells (TRM) and stem memory T cells. Rather than fixed cell fates, however, there is evidence that these 81 
phenotypes retain some degree of plasticity. The timing and determinants of the transitions between 82 
states are not fully understood, and remain an important area of investigation. Several markers have 83 
been clearly identified as strongly associated with a cell’s capacity for long-term survival, such as high 84 
expression of IL-7R and low expression of KLRG1. 85 
 86 
Assay methods 87 
Persisting antibody following vaccination is recognized as the first line of defense against 88 
subsequent infection and is regarded as a distinguishing characteristic of an effective vaccine [12].  All 89 
currently licensed anti-viral vaccines elicit a robust antibody response that correlates with the level of 90 
protection provided by the vaccine [13]. If the same should prove to be true for dengue, then the search 91 
for a CMI “correlate of protection” for dengue would be unnecessary. However, dengue is one of several 92 
globally important infectious diseases, along with HIV, malaria, and tuberculosis, for which a vaccine is 93 
highly desirable yet no validated animal model or correlate of immune protection is known. While 94 
empirical testing of candidate vaccines has been successful in the past, the era of molecular biology has 95 
led to an explosion of tools and methodologies for creating new vaccine antigens and vector delivery 96 
systems. The contribution of CMI, particularly T cells, to a successful dengue vaccine is highly likely 97 
whether it be as direct effector cells, provision of help for antibody development or creating a 98 
generalized anti-viral environment. Together with the antigenic complexity of candidate dengue 99 
vaccines (Table 2), assessing T cell responses presents a logistical problem for both vaccine developers 100 
and clinical testing laboratories – how to test or screen for all possible T cell functions when the most 101 
relevant function(s) are unknown. 102 
Fortunately, T cell-based immunoassay development has also proceeded at a remarkable rate 103 
[14, 15]. A list of assays together with their advantages and disadvantages is presented in Table 3. 104 
Recently the focus of immune-monitoring has been upon assays that provide “minimal manipulation.” 105 
Relatively high-throughput assays such as ELISPOT and intracellular cytokine staining (ICS), which utilize 106 
in vitro stimulation times of less than 24 hours (or no stimulation in the case of direct ex vivo flow 107 
cytometry), are the assays of choice as a screening tool. When well qualified, both platforms are 108 
quantitative and specific for the antigen. While validation of ELISPOT and ICS assays is not trivial, it is 109 
possible, and if a T cell-based correlate of protection for dengue is defined one of these platforms would 110 
most likely be the basis of such an assay [16, 17]. The general disadvantage of ELISPOT assays is that 111 
some a priori knowledge of the relevant functions is required. IFN- has been used extensively in vaccine 112 
development as a marker of vaccine take and as a function that is necessary, but perhaps not sufficient, 113 
for protection. ICS expands upon the functional profile of ELISPOT assays, bringing the concept of 114 
polyfunctionality of T cells to the fore. Again, some a priori knowledge of the relevant functional profile 115 
is required to fully interpret the results of this assay. Furthermore, ELISPOT and ICS assays are best 116 
suited for measuring and quantifying the direct effector capacity of T cells (IFN-, TNF, and cytolytic 117 
potential), but are significantly less sensitive at measuring T cell helper capacity. Mass cytometry and 118 
advanced polychromatic flow cytometry are technologies that permit the analysis of as many as 36 119 
parameters simultaneously on a single cell. These parameters may include both phenotypic and 120 
functional markers. While these methods will facilitate high-dimensional, quantitative analysis of 121 
biomolecules on cell populations at single-cell resolution, their application to dengue research has so far 122 
been limited [18, 19]. 123 
The most sensitive assays are generally those that involve proliferation of a small number of 124 
antigen-specific precursor cells. Dye-dilution based T cell proliferation, when appropriately calibrated, 125 
can identify the phenotype of proliferating T cells as well as quantify the precursor frequency [20]. In 126 
addition, cytokines associated with helper (e.g., IL-4, IL-5, IL-13, IL-21) or regulatory (e.g., IL-10, TGF-) 127 
capacity can be studied in supernatants collected from proliferation assays. This approach does however 128 
digress from the minimal manipulation concept, is less reproducible and is prone to in vitro variation 129 
artifact. 130 
Microfluidics-based technologies have led to the possibility of extensive transcriptional profiling 131 
of T cells at the single-cell level and a description of the population dynamics of T cell responses. While 132 
better suited to a research-based environment, these methodologies provide a discovery platform that 133 
will deliver the best opportunity to uncover a correlate of protection [21, 22]. Ultimately a thorough 134 
profiling of the entire “immune space” that is occupied by a dengue vaccine will be required to compare 135 
and contrast different vaccine modalities and vaccination strategies [23]. Describing the quality, quantity 136 
and durability of immune responses elicited will involve a standardized approach incorporating many of 137 
assay procedures listed above and probably new technologies as they become deployable. 138 
Should a CMI correlate of protection from dengue infection be identified, a significant effort will 139 
be required to qualify and validate assays platforms that will reliably detect and/or measure the 140 
correlate or function. As described earlier, validation of ELISpot or ICS format assays has proved 141 
possible; however, the further challenge will be applying these assays to meet the needs of the global 142 
dengue vaccine research community. The field would benefit from the establishment of centralized 143 
laboratory(s) that implement External Quality Assurance (EQA) Programs for overseeing the 144 
development of external proficiency testing programs for flow cytometry, ELISpot and other CMI-based 145 
assays [24-27]. EQA programs serve three purposes and are run according to Good Clinical Laboratory 146 
Practice (GCLP) guidance: 1) provide a means for laboratories to ensure that the data generated are 147 
accurate, timely and clinically relevant; 2) provide assurance to sponsors that the data is reliable and 148 
high quality; and 3) ensure the appropriate and accurate use of human specimens obtained from clinical 149 
trials. In addition to EQA programs, the establishment of biorepositories of standardized qualified 150 
reagents and antigens (e.g. PBMCs, peptide sets, viral isolates) for use in helping laboratories validate 151 
assays would be invaluable [28-30]. Such programs have proved successful for the field of HIV vaccine 152 
testing, with the EQAPOL program run by the NIH Division of AIDS, and the field of cancer T cell therapy, 153 
with the immunomonitoring program run by the Cancer Immunotherapy Consortium 154 
(http://www.cancerresearch.org/cic) [24, 31, 32]. 155 
 156 
T cell responses to DENV 157 
Human T cell responses to DENV were first characterized over 30 years ago, and many of the 158 
general principles originally described have remained consistent [33, 34]. Infection with one DENV 159 
induces both CD4 and CD8 memory T cells specific for DENV epitopes, with a small number of epitopes 160 
dominating the response in each individual. Epitopes are located throughout the DENV polyprotein, 161 
although several regions, especially the nonstructural protein 3 (NS3), appear to have a concentration of 162 
immunodominant epitopes. The amino acid homology across the four DENV serotypes varies for each 163 
epitope; however, most epitopes are well conserved among strains within the same serotype and differ 164 
at relatively few positions (1 to 3 of 9 residues) from the corresponding epitopes of other DENV 165 
serotypes (and other flaviviruses). The overall T cell response induced by a primary DENV infection is 166 
strongest to the serotype to which the subject had been exposed, but variable degrees of cross-167 
reactivity are usually observed to one or more of the other serotypes. 168 
Notwithstanding the confirmation of the above paradigms, the greater understanding of T cell 169 
biology and advancements in techniques for analysis of T cell responses described above have provided 170 
a more detailed and complex picture, particularly with regard to the different characteristics of the 171 
memory T cell response and their potential functions during the recall response to a subsequent DENV 172 
infection. Inasmuch as vaccination is intended to induce an immune response that will protect against 173 
infection or disease during a subsequent DENV exposure, these findings are highly relevant to evaluating 174 
the immunogenicity of different vaccine regimens. However, extrapolating observations from natural 175 
DENV infection to current vaccines is confounded by several important differences, as will be discussed 176 
further below. 177 
 178 
Survey of recent literature 179 
The pace of scientific publications describing the T lymphocyte response to DENV has greatly 180 
accelerated in recent years. A review of PubMed entries showed at least 38 papers published since 2005 181 
that analyzed human DENV-specific T cell responses based either on functional responses to stimulation 182 
by DENV antigens or staining by HLA-peptide tetramers containing DENV peptides, 26 of which have 183 
been published since 2010 [35-75]; papers that measured serum levels of cytokines or frequencies of 184 
lymphocyte subsets during acute DENV infection were not counted if the methods could not relate the 185 
findings with antigen specificity. Taking advantage of newer techniques, these papers have greatly 186 
expanded the number of individuals whose immune responses have been characterized- tens to 187 
hundreds of subjects in each study, in comparison to fewer than 10 in most of the earlier studies. The 188 
knowledge base of DENV-specific immune responses is thus more representative of the global 189 
population, particularly among populations in dengue-endemic areas. 190 
Several methodological trends are evident in the recent literature. ELISPOT and flow cytometry 191 
have become preferred assays; relatively few of the results from these assays- usually only for dominant 192 
responses- have been validated by analysis of epitope-specific T cell lines. All ELISPOT and cytokine flow 193 
cytometry studies have examined the production of IFN-. Studies using cytokine flow cytometry have in 194 
addition measured several other effector functions, in particular TNF, MIP-1, or IL-2 production or 195 
release of cytotoxic granules (measured by capture of CD107a at the cell surface). 196 
In vitro stimulation for detection of DENV-specific T cells was accomplished with synthetic 197 
peptides in nearly all of the recent studies. In comparison with crude antigen preparations used in 198 
earlier studies, such as DENV-infected cell lysates, synthetic peptides provide greater standardization 199 
and reproducibility, and also directly provide detailed epitope localization. The large number of peptides 200 
needed to provide a comprehensive analysis of all potential DENV epitopes presents a major technical 201 
challenge, however. None of the studies reviewed included overlapping peptides from the full 202 
proteomes of all four DENV serotypes. Weiskopf et al conducted the most comprehensive analysis [60]; 203 
however, although a total of 8,000 peptides were used in the study, each subject was only tested for 204 
recognition of a subset of peptides selected based on predictions of peptide binding to autologous HLA 205 
class I alleles. Epitope prediction algorithms were used in 8 other studies, but many fewer candidate 206 
epitopes were tested. Fourteen studies tested sets of overlapping peptides; of these, 4 studies tested 207 
peptides covering the full proteome of DENV-2, whereas the remaining studies tested overlapping 208 
peptides covering only a portion of the proteome, most often the NS3 protein. 209 
At least 10 studies have used HLA-peptide tetramers to analyze DENV-specific T cells either 210 
directly ex vivo or after in vitro expansion [36, 38, 42, 47-49, 52, 59, 66, 73]. However, six of these 211 
studied the same HLA-A*1101-restricted “GTS” epitope on the NS3 protein; in total, the remaining 4 212 
studies investigated 5 other CD8 T cell epitopes and 2 CD4 T cell epitopes. Thus, conclusions based on 213 
this body of data still are subject to considerable potential for bias. 214 
 215 
Contributions from animal models 216 
Differences between study populations in host genetics as well as prior DENV exposures 217 
continue to complicate the comparison of findings across studies. Given the difficulty in documenting or 218 
controlling these factors, there continues to be substantial interest in experimental animal models, 219 
particularly small, genetically defined animals such as mice. Several “humanized” mouse models have 220 
been studied. In several studies of transgenic mice expressing single HLA alleles, investigators 221 
demonstrated recognition of candidate epitopes that were selected for predicted HLA binding; 222 
subsequent testing of DENV-immune humans confirmed responses to some but not all of these epitopes 223 
[64, 69, 76-78]. Studies of immunodeficient mice in which human immune cells were reconstituted by 224 
transfusion of human hematopoietic stem cells detected T cell responses to a limited number of known 225 
human T cell epitopes [79, 80]. These studies provide preliminary evidence that these models might 226 
supplement human studies. Limited testing of heterologous secondary DENV infections was done in 227 
HLA-transgenic mice [78], but no comprehensive analysis of the different possible sequences of DENV 228 
infection has been conducted in these models to date. 229 
 230 
Epitope distribution and cross-reactivity 231 
Recent studies have greatly expanded the database of T cell epitopes identified on DENV 232 
proteins [81]. This reflects the combined effects of studying a larger number of humans with more 233 
diverse HLA alleles and prior DENV infection history as well as the application of single-cell assays such 234 
as ELISPOT with large numbers of synthetic peptides. It is difficult to directly compare the results from 235 
different studies, however, because of the confounding effects of differences in the numbers and 236 
characteristics of the peptides used. Overlapping peptides covering over 70% of the proteome of 237 
representative strains of all four DENV serotypes have been made available to the research community 238 
through an NIAID-funded reagent repository (www.beiresources.org), but these were not used in most 239 
of the published studies. Additionally, there remains a lack of consensus on the optimal criteria for 240 
defining epitopes. Immunodominant epitopes- those that induce responses of high magnitude in the 241 
majority (often nearly all) of subjects with the appropriate HLA allele- have generally shown similar 242 
results across studies, but these represent a minority of the epitopes identified and the generalizability 243 
of the observations regarding these epitopes needs to be verified. 244 
As mentioned above, the distribution of T cell epitopes across all DENV proteins, albeit with a 245 
predominance of epitopes on nonstructural proteins, has been reinforced by the expanded literature. A 246 
need to test for responses to the entire proteome of all four DENV serotypes presents challenges for 247 
performing large-scale testing of T cell responses, such as in the context of a phase II or III vaccine trial. 248 
In contrast, data pointing to the immunodominance of responses to particular regions of the polyprotein 249 
provide some support for more targeted testing. For example, Weiskopf et al have estimated that a pool 250 
of 268 peptides would include 90% or more of CD8 T cell epitopes in any study population [72]. 251 
However, this conclusion is based on their approach of HLA class I epitope prediction. It is reasonable to 252 
hypothesize that other immunologically important epitopes, especially HLA class II-restricted epitopes, 253 
have yet to be defined. Studies have yielded conflicting data on whether the distribution of CD4 T cell 254 
epitopes is similar or different from that of CD8 T cell epitopes [48, 57], with one study reporting that 255 
CD4 T cells more often recognized epitopes on structural proteins [57]. 256 
The use of single-cell assays such as ELISPOT has complicated the interpretation of serotype-257 
cross-reactivity of T cell responses, as these assays do not assess serotype-cross-reactivity at the level of 258 
individual cells. This is a particular problem in individuals who have been exposed to more than one 259 
DENV serotype, either through sequential exposure or multivalent immunization. Although one study 260 
concluded that serotype-specific epitopes could be defined based on sequence conservation alone [78], 261 
other experimental data are directly contradictory [36, 37, 41]. Another study described a panel of CD4 262 
T cell epitopes predicted to be serotype-specific based on high sequence divergence across serotypes 263 
[55]. Among participants in a cohort study, individuals who experienced an interval DENV infection 264 
acquired responses to peptides of one additional serotype [74]; however, only 7 subjects were studied 265 
and the DENV serotype causing the interval infection was not identified. 266 
Several recent findings underscore the importance of clinical, virologic, and epidemiologic data 267 
on individual subjects for the interpretation of T cell responses to DENV. Although measures of T cell 268 
responses at the population level consistently show stronger responses to the infecting DENV serotype 269 
after a primary DENV infection, exceptions to this pattern have been observed at the level of individual 270 
epitopes [37, 49, 52], and the patterns of cross-reactivity have been even more difficult to predict after 271 
secondary DENV infections. Several studies have also found sufficient sequence divergence within one 272 
or more DENV serotype(s) to affect the T cell response [67, 82], but the clinical significance of these 273 
observations is unknown. 274 
 275 
T cell subsets and their effector functions 276 
Recent studies using multiparameter flow cytometry have provided a more detailed picture of 277 
the effector T cell response to DENV. As noted above, most studies have focused on type 1 cytokine-278 
producing T cells (Th1/Tc1); these studies have revealed a high degree of heterogeneity in cytokine 279 
production at the individual cell level. While polyfunctional T cells expressing 3 or more effector 280 
functions have been observed, there are also substantial populations of cells expressing 1 or 2 of the 281 
functions measured, including cells expressing only cytokines with pro-inflammatory effects (TNF 282 
and/or -chemokines) [37, 49, 60, 67]. Stimulation with the corresponding epitopes of different DENV 283 
serotypes has been shown to alter the profile of cytokines produced, suggesting that variant epitopes 284 
act as altered peptide ligands for some DENV-specific T cells [36, 37]. 285 
Comparably less is known regarding effector responses other than Th1/Tc1. Of the few studies 286 
that reported data on the production of type 2 cytokines, most reported little or no production of IL-4 287 
except one study of very young children (mean age 7.7 months) [61]. Single studies have described 288 
production of IL-17 [61] or IL-21 [57] by T cells in response to stimulation, or have observed the 289 
expression of markers associated with follicular helper CD4 T cells [57] or T cells capable of homing to 290 
skin [73]. 291 
 292 
Primary vs. secondary infection 293 
Models of sequential infection with different DENV serotypes postulate that the immune 294 
response to secondary infection will differ in several important ways from that to the primary infection: 295 
a) the memory T cell response will be induced more rapidly and achieve higher levels, b) the memory 296 
response will preferentially activate T cells directed at epitopes that are more highly conserved between 297 
the different DENV serotypes, mainly on non-structural proteins, and c) the memory T cell response will 298 
have an altered effector profile reflecting differential activation by peptides from the second DENV 299 
serotype [83]. Although testing these postulates is highly relevant to understanding both protective and 300 
detrimental immune responses in dengue, only a few studies have compared immune responses during 301 
or after primary versus secondary DENV infections. Consistent with the predictions, differences have 302 
been reported in the expression of some phenotypic markers [71], in the dominant epitopes targeted 303 
[78], and in the profile of serotype cross-reactivity [52, 82]. Surprisingly, no significant differences were 304 
observed in the kinetics of the response or in the peak T cell frequencies during the acute infection [48, 305 
52]. These studies involved only symptomatic DENV infections, however, and the intrinsic incubation 306 
period prior to the onset of symptoms could not be determined. Also, the clearance of viremia may be 307 
more rapid in secondary infections, as suggested by some data [84]. These significant differences could 308 
have masked differences in the kinetics and magnitude of the immune response in primary versus 309 
secondary infections. 310 
 311 
Vaccines vs. natural infection 312 
With the expanding pipeline of vaccines in clinical testing and the wider availability of the 313 
requisite expertise and technology, there has been a growing body of literature describing the T cell 314 
response to dengue vaccines. All of the recently published studies have involved candidate live 315 
attenuated vaccines. These studies have shown that DENV-specific memory T cells, including 316 
polyfunctional Th1/Tc1 cells, are induced within 21 days after vaccination of flavivirus-naïve subjects 317 
[56]. In comparison to vaccination with its individual components, vaccination with the tetravalent 318 
formulation of the NIH/Butantan vaccine (Table 2) preferentially induced T cell responses to peptides 319 
from the more conserved non-structural proteins [70]. Interestingly, vaccination with the Sanofi Pasteur 320 
chimeric DENV-YFV vaccine induced T cell responses to epitopes on DENV NS3 protein in DENV-immune 321 
subjects but not in DENV-naïve subjects, suggesting that the heterologous YFV epitopes could reactivate 322 
pre-existing memory CD8 T cells but not antigen-inexperienced T cells [62]. Comparison of the T cell 323 
responses induced by the different dengue vaccines listed in Table 2 is not possible, however, because 324 
of significant differences in study and assay design. 325 
 326 
Potential contributions of T cell assays to dengue vaccine development  327 
The area where assessment of T cell responses to dengue vaccines would clearly have greatest 328 
impact is in identifying correlates of vaccine efficacy. A reliable immunological correlate of vaccine-329 
induced protective immunity would accelerate vaccine testing in different populations, regimens, or 330 
epidemiological contexts. The limitations of current neutralizing antibody assays reinforce the need for a 331 
better understanding of correlates of protective immunity, although the poor discriminant ability of 332 
neutralizing antibody titers may point either to deficiencies in the assay or to non-antibody protective 333 
mechanisms. Human cohort studies and animal experiments have found associations between T cell 334 
IFN- production and protective immunity [51, 60, 85, 86], supporting the potential to identify T cell 335 
responses associated with protective immunity induced by vaccination. However, the published data are 336 
quite limited. Only two studies correlated T cell responses in blood samples collected prior to exposure 337 
with clinical outcomes in individual subjects [51, 87]; both studies relied on the same prospective cohort 338 
and the sample sizes were small. Also, given the difficulty in defining individuals who are fully protected 339 
from infection, all subjects in these studies experienced DENV infections and comparisons were based 340 
on severity of illness (hospitalized dengue versus non-hospitalized dengue in one study and subclinical 341 
versus symptomatic infection in the other). Other studies measured T cell responses only during or after 342 
DENV infection, a significant confounding factor for any conclusions regarding causality. This concern is 343 
somewhat lessened in the case of experimental infection, where protective immunity was associated 344 
with early IFN- responses [88]. In light of the limitations of published data, however, it will be essential 345 
to validate immunological correlates against clinical endpoints in vaccine trials. 346 
It will be important to validate any immunological correlates independently for several different 347 
vaccines, because the associations between immunological readouts and vaccine efficacy may or may 348 
not be equivalent. In addition to the differences in immune response pathways that might be stimulated 349 
by live versus inactivated or subunit vaccines, there are significant differences in antigenic content 350 
among the dengue vaccines currently in clinical development (Table 2). This is most pronounced with 351 
regard to the repertoire of flavivirus non-structural (NS) proteins, with some vaccines containing no NS 352 
proteins (subunit and inactivated vaccines, although the latter may include some NS1 protein), some 353 
containing NS proteins of one flavivirus, either DENV2 or the heterologous YFV, and one containing NS 354 
proteins of 3 of 4 DENV serotypes. Since non-structural proteins contain the majority of T cell epitopes, 355 
the repertoire of T cell responses induced by each vaccine will likely differ as well, although the resulting 356 
immunological profile is difficult to predict at this stage. 357 
A second area where measurement of T cell responses could make an important contribution is 358 
in evaluating the durability of vaccine-induced protective immunity. This is likely to be of particular 359 
importance for dengue vaccines given the evidence that partial immunity increases the risk for more 360 
severe illness. Substantial insight has been gained into how the initial activation of T cells contributes to 361 
the establishment of both long-lasting T cell and B cell memory, and this process has been successfully 362 
manipulated with pharmaceuticals such as rapamycin in experimental models [89, 90]. Licensed 363 
vaccines against other diseases differ significantly in the durability of pathogen-specific antibodies and T 364 
cells [91]; through comprehensive “systems vaccinology” approaches, early indicators of antibody and T 365 
cell responses have been identified for several of these vaccines [92, 93], although further studies are 366 
needed to establish their ability to predict longer-term durability of the response. 367 
The single-cell resolution and potential to evaluate multiple T cell effector functions of newer 368 
assays offer the capacity to reveal extraordinary detail on the relationships between these responses. 369 
This capacity will likely be of special interest in the case of dengue vaccines, given the multivalent nature 370 
of dengue vaccines, the need to provide protective immunity against all four DENV serotypes, and the 371 
evidence that more severe dengue disease is associated with an inflammatory immune response. Data 372 
from several studies showing the induction of polyfunctional T cells by different tetravalent dengue 373 
vaccines are encouraging [56, 70, 75]. However, it is unclear whether the degree of ‘polyfunctionality’ 374 
described is optimal; similar frequencies of polyfunctional T cells are seen after natural DENV infection, a 375 
setting that does not reflect fully (i.e., tetravalent) protective immunity. Partial immunity to DENV 376 
present prior to vaccination, as was seen in the majority of subjects in phase III vaccine trials in endemic 377 
areas [3, 4], could also modify the pattern of T cell effector functions. 378 
 379 
Conclusions and recommendations  380 
Although assessments of pathogen-specific T cell responses have not been a priority in most 381 
vaccine development efforts, we argue that dengue is a special case and that planning and preparation 382 
for such assessments should be given greater emphasis. The example of natural infection illustrates the 383 
potential for both positive (protective) and negative (pathological) effects of partial immunity to DENV, 384 
and potential concerns for long-term safety will likely remain a major impediment to licensure and 385 
widespread uptake of dengue vaccines. The current understanding of T cell responses to DENV indicates 386 
the potential for evaluations of T cell responses to accelerate vaccine design and testing by helping to 387 
identify correlates of vaccine efficacy and also to reduce the risk to vaccine developers by helping to 388 
understand negative outcomes of vaccine trials, should they occur [94]. Implementing analyses of T cell 389 
responses in the context of upcoming dengue vaccine trials will present a number of significant logistical 390 
challenges (Table 4). Based on current knowledge, it is not possible to define the assay or assays that 391 
would reliably serve all of the pertinent objectives. The experience from prospective dengue cohort 392 
studies [51, 87] and trials of other vaccines [95] does provide guidance to vaccine developers as to how 393 
T cell studies can be incorporated into dengue vaccine trials. There continues to be a need for studies of 394 
natural DENV infection as well as efforts to develop new technologies for assessment of T cell responses 395 
to DENV. Implementation of these efforts will require ongoing support from government, industry, and 396 
charitable foundations, as well as creative solutions from the scientific community. 397 
  398 
Disclaimer 399 
The opinions or assertions contained herein are the private views of the authors and are not to 400 
be construed as reflecting the official views of the United States Army or the United States Department 401 
of Defense. 402 
  403 
References 404 
 405 
[1] Plotkin SA. Correlates of protection induced by vaccination. Clinical and vaccine immunology : CVI. 406 
2010;17:1055-65. 407 
[2] Thomas SJ, Hombach J, Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue 408 
and dengue vaccine development. Vaccine. 2009;27:355-68. 409 
[3] Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical 410 
efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, 411 
randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358-65. 412 
[4] Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent 413 
dengue vaccine in children in Latin America. The New England journal of medicine. 414 
2015;372:113-23. 415 
[5] Kara EE, Comerford I, Fenix KA, Bastow CR, Gregor CE, McKenzie DR, et al. Tailored immune 416 
responses: novel effector helper T cell subsets in protective immunity. PLoS pathogens. 417 
2014;10:e1003905. 418 
[6] Tripathi SK, Lahesmaa R. Transcriptional and epigenetic regulation of T-helper lineage specification. 419 
ImmunolRev. 2014;261:62-83. 420 
[7] Cheroutre H, Husain MM. CD4 CTL: living up to the challenge. SemImmunol. 2013;25:273-81. 421 
[8] Peck A, Mellins ED. Plasticity of T-cell phenotype and function: the T helper type 17 example. 422 
Immunology. 2010;129:147-53. 423 
[9] Restifo NP, Gattinoni L. Lineage relationship of effector and memory T cells. CurrOpinImmunol. 424 
2013;25:556-63. 425 
[10] Gasper DJ, Tejera MM, Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev 426 
Immunol. 2014;34:121-46. 427 
[11] Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell 428 
differentiation. Nature immunology. 2014;15:1104-15. 429 
[12] Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055-430 
65. 431 
[13] Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine 432 
induced immune responses. Vaccine. 2012;30:4907-20. 433 
[14] Finak G, Jiang W, Krouse K, Wei C, Sanz I, Phippard D, et al. High-throughput flow cytometry data 434 
normalization for clinical trials. Cytometry A. 2014;85:277-86. 435 
[15] Saade F, Gorski SA, Petrovsky N. Pushing the frontiers of T-cell vaccines: accurate measurement of 436 
human T-cell responses. Expert Rev Vaccines. 2012;11:1459-70. 437 
[16] Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, et al. Detection of HIV vaccine-induced cell-438 
mediated immunity in HIV-seronegative clinical trial participants using an optimized and 439 
validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007;45:20-7. 440 
[17] Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, et al. Optimization and validation of an 441 
8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by 442 
vaccination. J Immunol Methods. 2007;323:39-54. 443 
[18] Bjornson ZB, Nolan GP, Fantl WJ. Single-cell mass cytometry for analysis of immune system 444 
functional states. Curr Opin Immunol. 2013;25:484-94. 445 
[19] Chattopadhyay PK, Roederer M. A mine is a terrible thing to waste: high content, single cell 446 
technologies for comprehensive immune analysis. Am J Transplant. 2015;15:1155-61. 447 
[20] Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry A. 448 
2011;79:95-101. 449 
[21] Plessy C, Desbois L, Fujii T, Carninci P. Population transcriptomics with single-cell resolution: a new 450 
field made possible by microfluidics: a technology for high throughput transcript counting and 451 
data-driven definition of cell types. Bioessays. 2013;35:131-40. 452 
[22] Trautmann L, Sekaly RP. Solving vaccine mysteries: a systems biology perspective. Nat Immunol. 453 
2011;12:729-31. 454 
[23] Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, et al. The immune space: a concept 455 
and template for rationalizing vaccine development. AIDS Res Hum Retroviruses. 2014;30:1017-456 
22. 457 
[24] Todd CA, Sanchez AM, Garcia A, Denny TN, Sarzotti-Kelsoe M. Implementation of Good Clinical 458 
Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight 459 
Laboratory (EQAPOL). J Immunol Methods. 2014;409:91-8. 460 
[25] Sanchez AM, Denny TN, O'Gorman M. Introduction to a Special Issue of the Journal of 461 
Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial 462 
studies. J Immunol Methods. 2014;409:1-5. 463 
[26] Staats JS, Enzor JH, Sanchez AM, Rountree W, Chan C, Jaimes M, et al. Toward development of a 464 
comprehensive external quality assurance program for polyfunctional intracellular cytokine 465 
staining assays. J Immunol Methods. 2014;409:44-53. 466 
[27] Rountree W, Vandergrift N, Bainbridge J, Sanchez AM, Denny TN. Statistical methods for the 467 
assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry. J Immunol 468 
Methods. 2014;409:72-81. 469 
[28] Sambor A, Garcia A, Berrong M, Pickeral J, Brown S, Rountree W, et al. Establishment and 470 
maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine 471 
trials. J Immunol Methods. 2014;409:107-16. 472 
[29] Sanchez AM, DeMarco CT, Hora B, Keinonen S, Chen Y, Brinkley C, et al. Development of a 473 
contemporary globally diverse HIV viral panel by the EQAPOL program. J Immunol Methods. 474 
2014;409:117-30. 475 
[30] Garcia A, Keinonen S, Sanchez AM, Ferrari G, Denny TN, Moody MA. Leukopak PBMC sample 476 
processing for preparing quality control material to support proficiency testing programs. J 477 
Immunol Methods. 2014;409:99-106. 478 
[31] Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, et al. T cell assays and 479 
MIATA: the essential minimum for maximum impact. Immunity. 2012;37:1-2. 480 
[32] Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, et al. "MIATA"-minimal 481 
information about T cell assays. Immunity. 2009;31:527-8. 482 
[33] Kurane I, Ennis FA. Immunity and immunopathology in dengue virus infections. SemImmunol. 483 
1992;4:121-7. 484 
[34] Rothman AL. Immunology and immunopathogenesis of dengue disease. Adv Virus Res. 485 
2003;60:397-419. 486 
[35] Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao le TT, et al. Early T-cell responses to dengue 487 
virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol. 488 
2005;79:5665-75. 489 
[36] Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to 490 
heterologous serotypes. J Immunol. 2005;175:2676-83. 491 
[37] Bashyam HS, Green S, Rothman AL. Dengue virus-reactive CD8+ T cells display quantitative and 492 
qualitative differences in their response to variant epitopes of heterologous viral serotypes. J 493 
Immunol. 2006;176:2817-24. 494 
[38] Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, et al. 495 
T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol. 496 
2006;176:3821-9. 497 
[39] de la CSB, Garcia G, Perez AB, Morier L, Alvarez M, Kouri G, et al. Ethnicity and difference in dengue 498 
virus-specific memory T cell responses in Cuban individuals. Viral Immunol. 2006;19:662-8. 499 
[40] Appanna R, Huat TL, See LL, Tan PL, Vadivelu J, Devi S. Cross-reactive T-cell responses to the 500 
nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever 501 
patients in Malaysia. Clinical and vaccine immunology : CVI. 2007;14:969-77. 502 
[41] Imrie A, Meeks J, Gurary A, Sukhbataar M, Kitsutani P, Effler P, et al. Differential functional avidity 503 
of dengue virus-specific T-cell clones for variant peptides representing heterologous and 504 
previously encountered serotypes. J Virol. 2007;81:10081-91. 505 
[42] Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, Peng Y, et al. High pro-inflammatory cytokine 506 
secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary 507 
dengue virus infection. PLoS ONE. 2007;2:e1192. 508 
[43] Wen JS, Jiang LF, Zhou JM, Yan HJ, Fang DY. Computational prediction and identification of dengue 509 
virus-specific CD4(+) T-cell epitopes. Virus research. 2008;132:42-8. 510 
[44] Moran E, Simmons C, Vinh Chau N, Luhn K, Wills B, Dung NP, et al. Preservation of a critical epitope 511 
core region is associated with the high degree of flaviviral cross-reactivity exhibited by a dengue-512 
specific CD4+ T cell clone. Eur J Immunol. 2008;38:1050-7. 513 
[45] Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, et al. Cell-mediated immunity induced 514 
by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 515 
2008;26:5712-21. 516 
[46] Wen J, Duan Z, Jiang L. Identification of a dengue virus-specific HLA-A*0201-restricted CD8+ T cell 517 
epitope. JMedVirol. 2010;82:642-8. 518 
[47] Dung NT, Duyen HT, Thuy NT, Ngoc TV, Chau NV, Hien TT, et al. Timing of CD8+ T cell responses in 519 
relation to commencement of capillary leakage in children with dengue. J Immunol. 520 
2010;184:7281-7. 521 
[48] Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, 522 
et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl 523 
Acad Sci U S A. 2010;107:16922-7. 524 
[49] Friberg H, Burns L, Woda M, Kalayanarooj S, Endy TP, Stephens HA, et al. Memory CD8(+) T cells 525 
from naturally acquired primary dengue virus infection are highly cross-reactive. ImmunolCell 526 
Biol. 2011;89:122-9. 527 
[50] Sun P, Beckett C, Danko J, Burgess T, Liang Z, Kochel T, et al. A dendritic cell-based assay for 528 
measuring memory T cells specific to dengue envelope proteins in human peripheral blood. 529 
JVirolMeth. 2011;173:175-81. 530 
[51] Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. Intracellular cytokine production by 531 
dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. 532 
2011;203:1282-91. 533 
[52] Friberg H, Bashyam H, Toyosaki-Maeda T, Potts JA, Greenough T, Kalayanarooj S, et al. Cross-534 
reactivity and expansion of dengue-specific T cells during acute primary and secondary 535 
infections in humans. Sci Rep. 2011;1:51. 536 
[53] Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J, Kamal S, et al. Conserved MHC class I-537 
presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-538 
serotype reactive T-cell response. The Journal of infectious diseases. 2012;205:647-55. 539 
[54] Malavige GN, Huang LC, Salimi M, Gomes L, Jayaratne SD, Ogg GS. Cellular and cytokine correlates 540 
of severe dengue infection. PLoS ONE. 2012;7:e50387. 541 
[55] Malavige GN, McGowan S, Atukorale V, Salimi M, Peelawatta M, Fernando N, et al. Identification of 542 
serotype-specific T cell responses to highly conserved regions of the dengue viruses. 543 
ClinExpImmunol. 2012;168:215-23. 544 
[56] Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, et al. Primary 545 
vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T 546 
cell response in humans. PLoS neglected tropical diseases. 2012;6:e1742. 547 
[57] Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, et al. Differential targeting of viral 548 
components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. JVirol. 549 
2013;87:2693-706. 550 
[58] Rivino L, Tan AT, Chia A, Kumaran EA, Grotenbreg GM, MacAry PA, et al. Defining CD8+ T cell 551 
determinants during human viral infection in populations of Asian ethnicity. JImmunol. 552 
2013;191:4010-9. 553 
[59] Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, et al. Conditional ligands for Asian HLA variants 554 
facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. 555 
EurJImmunol. 2013;43:1109-20. 556 
[60] Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. 557 
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective 558 
role for CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of 559 
America. 2013;110:E2046-53. 560 
[61] Talarico LB, Bugna J, Wimmenauer V, Espinoza MA, Quipildor MO, Hijano DR, et al. T helper type 2 561 
bias and type 17 suppression in primary dengue virus infection in infants and young children. 562 
TransRoyal SocTropMedHyg. 2013;107:411-9. 563 
[62] Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, et al. 564 
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and 565 
adolescents in Singapore. Hum Vaccin Immunother. 2013;9:2317-25. 566 
[63] Malavige GN, Jeewandara C, Alles KM, Salimi M, Gomes L, Kamaladasa A, et al. Suppression of virus 567 
specific immune responses by IL-10 in acute dengue infection. PLoS neglected tropical diseases. 568 
2013;7:e2409. 569 
[64] Nascimento EJ, Mailliard RB, Khan AM, Sidney J, Sette A, Guzman N, et al. Identification of 570 
conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS neglected tropical diseases. 571 
2013;7:e2497. 572 
[65] Nguyen TH, Nguyen TH, Vu TT, Farrar J, Hoang TL, Dong TH, et al. Corticosteroids for dengue - why 573 
don't they work? PLoS neglected tropical diseases. 2013;7:e2592. 574 
[66] Townsley E, Woda M, Thomas SJ, Kalayanarooj S, Gibbons RV, Nisalak A, et al. Distinct activation 575 
phenotype of a highly conserved novel HLA-B57-restricted epitope during dengue virus 576 
infection. Immunology. 2014;141:27-38. 577 
[67] Piazza P, Campbell D, Marques E, Hildebrand WH, Buchli R, Mailliard R, et al. Dengue virus-infected 578 
human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. 579 
ClinExpImmunol. 2014;177:696-702. 580 
[68] Comber JD, Karabudak A, Huang X, Piazza PA, Marques ET, Philip R. Dengue virus specific dual HLA 581 
binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum Vaccin 582 
Immunother. 2014;10:3531-43. 583 
[69] Duan Z, Guo J, Huang X, Liu H, Chen X, Jiang M, et al. Identification of cytotoxic T lymphocyte 584 
epitopes in dengue virus serotype 1. JMedVirol. 2015;87:1077-89. 585 
[70] Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters B, et al. The human CD8+ T cell responses 586 
induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved 587 
epitopes. JVirol. 2015;89:120-8. 588 
[71] Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, et al. Dengue virus infection 589 
elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. 590 
Proceedings of the National Academy of Sciences of the United States of America. 591 
2015;112:E4256-63. 592 
[72] Weiskopf D, Cerpas C, Angelo MA, Bangs DJ, Sidney J, Paul S, et al. Human CD8+ T-Cell Responses 593 
Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets. 594 
The Journal of infectious diseases. 2015. 595 
[73] Rivino L, Kumaran EA, Thein TL, Too CT, Gan VC, Hanson BJ, et al. Virus-specific T lymphocytes home 596 
to the skin during natural dengue infection. Sci Transl Med. 2015;7:278ra35. 597 
[74] Jeewandara C, Adikari TN, Gomes L, Fernando S, Fernando RH, Perera MK, et al. Functionality of 598 
dengue virus specific memory T cell responses in individuals who were hospitalized or who had 599 
mild or subclinical dengue infection. PLoS neglected tropical diseases. 2015;9:e0003673. 600 
[75] Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD. CD8+ T-cell Responses in Flavivirus-Naive 601 
Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine 602 
Candidate. The Journal of infectious diseases. 2015. 603 
[76] Duan ZL, Liu HF, Huang X, Wang SN, Yang JL, Chen XY, et al. Identification of conserved and HLA-604 
A*2402-restricted epitopes in Dengue virus serotype 2. Virus research. 2015;196:5-12. 605 
[77] Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, Sidney J, et al. Insights into HLA-606 
restricted T cell responses in a novel mouse model of dengue virus infection point toward new 607 
implications for vaccine design. J Immunol. 2011;187:4268-79. 608 
[78] Weiskopf D, Angelo MA, Sidney J, Peters B, Shresta S, Sette A. Immunodominance changes as a 609 
function of the infecting dengue virus serotype and primary versus secondary infection. JVirol. 610 
2014;88:11383-94. 611 
[79] Jaiswal S, Pearson T, Friberg H, Shultz LD, Greiner DL, Rothman AL, et al. Dengue virus infection and 612 
virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. 613 
PLoS ONE. 2009;4:e7251. 614 
[80] Jaiswal S, Pazoles P, Woda M, Shultz LD, Greiner DL, Brehm MA, et al. Enhanced humoral and HLA-615 
A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology. 616 
2012;136:334-43. 617 
[81] Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A. Meta-analysis of all immune epitope data in 618 
the Flavivirus genus: inventory of current immune epitope data status in the context of virus 619 
immunity and immunopathology. Viral Immunol. 2010;23:259-84. 620 
[82] Mongkolsapaya J, Dejnirattisai W, Xu X, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et 621 
al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature 622 
Med. 2003;9:921-7. 623 
[83] Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease 624 
pathogenesis. Curr Top Microbiol Immunol. 2010;338:83-98. 625 
[84] Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia 626 
titer, antibody response pattern and virus serotype correlate with disease severity. JInfectDis. 627 
2000;181:2-9. 628 
[85] Gil L, Bernardo L, Pavon A, Izquierdo A, Valdes I, Lazo L, et al. Recombinant nucleocapsid-like 629 
particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. The 630 
Journal of general virology. 2012;93:1204-14. 631 
[86] Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, et al. CD4+ T cells are not 632 
required for the induction of dengue virus-specific CD8+ T cell or antibody responses but 633 
contribute to protection after vaccination. J Immunol. 2010;185:5405-16. 634 
[87] Mangada MM, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Libraty DH, et al. Dengue-specific T 635 
cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus 636 
infections in Thai schoolchildren. JInfectDis. 2002;185:1697-703. 637 
[88] Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A, et al. A human challenge 638 
model for dengue infection reveals a possible protective role for sustained interferon gamma 639 
levels during the acute phase of illness. Vaccine. 2011;29:3895-904. 640 
[89] Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates 641 
memory CD8 T-cell differentiation. Nature. 2009;460:108-12. 642 
[90] Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, et al. Sirolimus enhances the 643 
magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in 644 
rhesus macaques. Am J Transplant. 2011;11:613-8. 645 
[91] Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine 646 
antigens. The New England journal of medicine. 2007;357:1903-15. 647 
[92] Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach 648 
predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology. 649 
2009;10:116-25. 650 
[93] Tan Y, Tamayo P, Nakaya H, Pulendran B, Mesirov JP, Haining WN. Gene signatures related to B-cell 651 
proliferation predict influenza vaccine-induced antibody response. EurJImmunol. 2014;44:285-652 
95. 653 
[94] Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. 654 
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. The New 655 
England journal of medicine. 2015. 656 
[95] Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates 657 
analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275-86. 658 
 659 
  660 








Th1 IFN- CXCR3 T-Bet Cellular immunity 
Th2 IL-4, IL-5, IL-13 CCR3, CCR4, 
CCR8 
GATA-3 Humoral immunity 
Th17 IL-17 CCR2, CCR4, 
CCR6 
RORt Inflammation 
Th9 IL-9 CCR3, CCR6, 
CXCR3 
PU.1 Mucosal immunity 
Th22 IL-22 CCR4, CCR10 AhR Parasites 
Tfh IL-21 CXCR5 Bcl-6 B cell help 
iTreg IL-10, TGF- CCR6 FoxP3 Immunosuppression, tolerance 
 662 
  663 
Table 2. T cell antigenic content of dengue vaccine candidates in clinical development. 664 
Vaccine developer Structural proteins Non-structural proteins 
Live, attenuated (chimeric 
flaviviruses) 
  
Sanofi Pasteur C: YFV; pre-M, E: DENV1-4 NS1-5: YFV 
Takeda C: DENV2; pre-M, E: DENV1-4 NS1-5: DENV2 
NIH/Butantan C: DENV1/3/4; pre-M, E: DENV1-
4 
NS1-5: DENV1/3/4 
Purified inactivated   
WRAIR/GSK C, pre-M, E: DENV1-4 None (? NS1) 
Subunit   
Merck E (80%): DENV1-4 None 
 665 
  666 
Table 3. Advantages and disadvantages of different methodologies for evaluation of pathogen-specific T 667 
cell responses. 668 
Method Functions measured Advantages Disadvantages 






Quantitative readout of 
cell frequency 
Independent of cell 
responsiveness 
Limited to one or few 
epitopes 
Not reflective of cell 
function 
Costly 
    
Short-term in vitro (1 
day) 
















ELISPOT Cytokine secretion 
Granzyme release 






One (or two) functions 




Any function (based on 
gene expression) 
Gene networks 
controlling cell fate 
Provides complete 






Data analysis requires 
bioinformatics 
expertise 
    
Extended in vitro (5+ 
days) 
   






One (or two) functions 
assessed per cell 
Cell frequency altered 
by stimulation 
Flow cytometry (marker 
dilution) 










Immunoassay Cytokine secretion 
Granzyme release 
Technical ease 
Can be multiplexed 
Low sensitivity for rare 
cells 
Cloning (characterize 
with other assays) 









  670 
Table 4. Logistical issues and recommendations for assessment of T cell responses to dengue vaccines. 671 
Issues Recommendations 
Technical expertise and infrastructure needed for 
collection of viable PBMC 
Study site development and staff training and 
supervision 
Need to measure responses to all four DENV 
serotypes (and separately for structural 
and non-structural antigens) 
Collect adequate volumes of blood for assessment 
of T cell responses 
Immune correlates of vaccine efficacy have not yet 
been defined 
Apply a diverse suite of assays of T cell function 
and specificity 
Variation in HLA alleles and prior DENV exposure 
history in vaccine recipients 
Enroll adequate numbers and diversity of subjects 
in assessments of T cell responses to 
vaccination 
Collect blood samples before and after vaccination 
for T cell assays 
Lack of high-throughput assays to measure cross-
reactivity at single-cell level 
Development of new assay technologies 
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